By Professor Jerry Richard Greenfield

Book Chapters

Greenfield JR; Samocha-Bonet D, 2015, 'Glutamine and glucagon-like peptide-1 response', in Rajendram R; Preedy VR; Patel VB (ed.), Glutamine in Clinical Nutrition, Springer, London

Journal articles

Shoung N; Carette C; Rassy N; Phan A; Greenfield JR; Hu FB; Rives-Lange C; Czernichow S, 2025, 'Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions', Scientific Reports, 15, http://dx.doi.org/10.1038/s41598-025-00080-9

JANUSZEWSKI AS; SIMONSEN JRA; GRZELKA-WOZNIAK A; SNAITH JR; SACHITHANANDAN N; WARD GM; O'NEAL DN; THORN LM; JENKINS A; GREENFIELD J; URUSKA A; ZOZULINSKA-ZIOLKIEWICZ D; GROOP P-H, 2025, '1584-P: Euglycemic Hyperinsulinemic Clamps Reveal Lower Insulin Sensitivity in Type 1 Diabetes Adults with vs. without Nephropathy', Diabetes, 74, http://dx.doi.org/10.2337/db25-1584-p

MILDER TY; SHEPHERD L; PEARSON S-A; KRISTIAN RÅKET H; GREENFIELD J; DAY RO; LIN J; POLLOCK CA; NEUEN B; JUN MIN; DE OLIVEIRA COSTA J; STOCKER S; LUDINGTON J; FALSTER MO, 2025, '904-P: Hospitalization Is a Risk Factor for SGLT2i Discontinuation', Diabetes, 74, http://dx.doi.org/10.2337/db25-904-p

Mathews KO; MacMillan F; Wong V; Craig M; Greenfield JR; Hicks R; Jones T; Poynten A; Wong T; Reyes M; Tannous K; Wilson C; Hay P; Abdo S; Piya MK; Lai J; Venigalla M; Thomson R; Simmons D, 2025, 'Study protocol: Apps and peer support for a healthy future and living well with diabetes (APHLID-M)', Contemporary Clinical Trials Communications, 45, http://dx.doi.org/10.1016/j.conctc.2025.101484

Lin J; Milder TY; Deakin CT; de Oliveira Costa J; Havard A; Neuen BL; Buckley NA; Brieger D; Greenfield JR; Jun M; Day RO; Pearson SA; Falster MO, 2025, 'Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study', Diabetes Research and Clinical Practice, 224, pp. 112242, http://dx.doi.org/10.1016/j.diabres.2025.112242

Raven LM; Lever W; MacIsaac RJ; Greenfield JR; Deane A; Plummer M; Umapathysivam M, 2025, 'Heterogeneity in the management of diabetic ketoacidosis in Australia: a national survey', Internal Medicine Journal, 55, pp. 728 - 733, http://dx.doi.org/10.1111/imj.70024

Raven LM; Greenfield JR; Jabbour A; Macdonald PS; Muir CA, 2025, 'Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation', Jhlt Open, 8, http://dx.doi.org/10.1016/j.jhlto.2025.100255

Shah VN; Agesen RM; Bardtrum L; Christiansen E; Snaith J; Greenfield JR, 2025, 'Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies', Journal of Diabetes Science and Technology, 19, pp. 321 - 331, http://dx.doi.org/10.1177/19322968241305647

Brzozowska MM; Bliuc D; Mazur A; Baldock PA; Eisman JA; Greenfield JR; Center JR, 2025, 'Response to the Letter by Yi Wang: “Reflections on ‘sex-differential testosterone response to long-term weight loss’: illuminating findings and considered limitations”: Bariatric Surgery', International Journal of Obesity, 49, pp. 538 - 539, http://dx.doi.org/10.1038/s41366-024-01692-3

Milder TY; Lin J; Pearson SA; de Oliveira Costa J; Neuen BL; Pollock C; Jun M; Greenfield JR; Day RO; Stocker SL; Brieger D; Falster MO, 2025, 'Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?', Diabetes Obesity and Metabolism, 27, pp. 997 - 1000, http://dx.doi.org/10.1111/dom.16061

Greenfield JR; Frampton R; Millard K; Snaith JR, 2025, 'Use of Cardioprotective Adjuncts in Type 1 Diabetes', Diabetes Therapy, 16, pp. 145 - 148, http://dx.doi.org/10.1007/s13300-024-01687-3

De Sousa SMC; Davis TME; Harraway J; Greenslade M; Wu KHC; Paul RG; Taylor J; Ali AS; Ekinci EI; Murphy R; Greenfield JR, 2025, 'Australian and New Zealand joint society consensus statement on genetic testing for monogenic diabetes in adults', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.52717

Frampton R; Lewis D; Rahman Y; Tchan M; Greenfield JR, 2025, 'Hypoglycaemia following physical exercise in a patient with novel SLC16A1 variant', European Journal of Endocrinology, 192, pp. K1 - K5, http://dx.doi.org/10.1093/ejendo/lvae159

Januszewski AS; Snaith JR; Grzelka-Wozniak A; Simonsen JRA; Sachithanandan N; Ward GM; O'Neal DN; Gordin D; Thorn LM; Groop PH; Uruska AA; Zozulinska-Ziolkiewicz DA; Jenkins AJ; Greenfield JR, 2025, 'No evidence from euglycaemic–hyperinsulinaemic clamp studies for greater insulin sensitivity in adults with type 1 diabetes using insulin pump versus multiple daily insulin injections—Post hoc meta-analysis', Diabetes Obesity and Metabolism, http://dx.doi.org/10.1111/dom.16487

Frampton R; Hocking S; Snaith JR; Greenfield JR, 2025, 'Targeting cardiometabolic risk in type 1 diabetes through incretin physiology', Trends in Endocrinology and Metabolism, http://dx.doi.org/10.1016/j.tem.2025.06.004

Milder TY; Lin J; Pearson SA; Greenfield JR; Day RO; Stocker SL; Neuen BL; Falster MO; de Oliveira Costa J, 2025, 'Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018–2022', British Journal of Clinical Pharmacology, 91, pp. 117 - 126, http://dx.doi.org/10.1111/bcp.16231

de Oliveira Costa J; Lin J; Milder TY; Havard A; Greenfield JR; Day RO; Neuen BL; Gibson AA; Morton JI; Sacre JW; Pearson SA; Falster MO, 2025, 'Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk', European Journal of Clinical Pharmacology, pp. 1 - 13, http://dx.doi.org/10.1007/s00228-025-03870-2

Shen I; Stojanova J; Yeo M; Olsen N; Lockart I; Wang M; Roggeveld J; Heerspink HJL; Greenfield JR; Day R; Danta M, 2024, 'A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease', British Journal of Clinical Pharmacology, 90, pp. 2529 - 2538, http://dx.doi.org/10.1111/bcp.16139

Patel SK; Fourlanos S; Greenfield JR, 2024, 'Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care 2024;47:770–781', Diabetes Care, 47, http://dx.doi.org/10.2337/dc24-1388

Brzozowska MM; Bliuc D; Mazur A; Baldock PA; Eisman JA; Greenfield JR; Center JR, 2024, 'Correction: Sex-differential testosterone response to long-term weight loss (International Journal of Obesity, (2024), 10.1038/s41366-024-01591-7)', International Journal of Obesity, 48, pp. 1514, http://dx.doi.org/10.1038/s41366-024-01597-1

Sriravindrarajah A; Hurwitz J; Lim E; Greenfield JR, 2024, 'Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition', Endocrinology Diabetes and Metabolism Case Reports, 2024-October, http://dx.doi.org/10.1530/EDM-24-0040

Frampton R; Snaith JR; Hocking S; Holmes-Walker J; Olsen N; Greenfield JR, 2024, 'Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial', Diabetic Medicine, 41, http://dx.doi.org/10.1111/dme.15377

Brzozowska MM; Bliuc D; Mazur A; Baldock PA; Eisman JA; Greenfield JR; Center JR, 2024, 'Sex-differential testosterone response to long-term weight loss', International Journal of Obesity, 48, pp. 1481 - 1488, http://dx.doi.org/10.1038/s41366-024-01591-7

Raven LM; Muir CA; Deveza RC; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Hayward CS; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation', Jhlt Open, 5, http://dx.doi.org/10.1016/j.jhlto.2024.100088

de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO, 2024, 'Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia', Diabetes Obesity and Metabolism, 26, pp. 2787 - 2795, http://dx.doi.org/10.1111/dom.15597

JANUSZEWSKI AS; SNAITH JR; KOWALSKI GM; BRUCE C; HOLMES-WALKER J; JENKINS A; GREENFIELD J, 2024, '1607-P: Estimation of Muscle and Hepatic Insulin Sensitivity in Type 1 Diabetes Adults Using Clinical and Research Biomarkers', Diabetes, 73, http://dx.doi.org/10.2337/db24-1607-p

FRAMPTON R; SNAITH JR; HOCKING SL; GREENFIELD J, 2024, '787-P: Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)—A Double-Blinded Randomized Placebo-Controlled Trial (Study Protocol)', Diabetes, 73, http://dx.doi.org/10.2337/db24-787-p

SNAITH JR; OLSEN ND; KOWALSKI GM; BRUCE C; EVANS JL; JANUSZEWSKI AS; JENKINS A; BREIT SN; HOLMES-WALKER J; GREENFIELD J, 2024, '865-P: Metformin Reduces Insulin Dose and Visceral Fat Accumulation, and Increases GDF15 without Reducing Insulin Resistance in Adults with Type 1 Diabetes—A 26-Week, Randomized, Double-Blind Placebo-Controlled Trial (INTIMET)', Diabetes, 73, http://dx.doi.org/10.2337/db24-865-p

O'Donnell JEM; Hastings LA; Briody JN; Chan CL; Colombo C; Douglas TA; Freedman SD; Gonska T; Greenfield JR; Leung DH; Lim AYL; Moran A; Prentice BJ; Putman MS; Trotter M; Tullis E; Westall GP; Verge CF; Wainwright CE; Ooi CY; Engelhardt JF; Katz T; King S; Lewindon PJ; Matson AG; McDonald CM; Moheet A; Narkewicz MR; Oliver M; Ramm GA; Sellers ZM; Wilschanski M, 2024, 'SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium', Pediatric Pulmonology, 59, pp. 1661 - 1676, http://dx.doi.org/10.1002/ppul.26970

Raven LM; Cao JY; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Fournier's gangrene in recent transplant recipient on empagliflozin', Jhlt Open, 4, http://dx.doi.org/10.1016/j.jhlto.2024.100060

Forner P; Snaith J; Greenfield JR, 2024, 'Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists', Internal Medicine Journal, 54, pp. 779 - 785, http://dx.doi.org/10.1111/imj.16312

Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR, 2024, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal, 54, pp. 559 - 567, http://dx.doi.org/10.1111/imj.16203

Lasschuit JWJ; Center JR; Greenfield JR; Tonks KTT, 2024, 'Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial', Journal of Diabetes and Its Complications, 38, http://dx.doi.org/10.1016/j.jdiacomp.2024.108718

Patel SK; Fourlanos S; Greenfield JR, 2024, 'Classification of type 1 diabetes: A pathogenic and treatment-based classification', Diabetes and Metabolic Syndrome Clinical Research and Reviews, 18, http://dx.doi.org/10.1016/j.dsx.2024.102986

Raven LM; Brown C; Greenfield JR, 2024, 'Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists', Medical Journal of Australia, 220, pp. 14 - 16, http://dx.doi.org/10.5694/mja2.52170

Muir CA; Kuang W; Muthiah K; Greenfield JR; Raven LM, 2024, 'Association of early post-transplant hyperglycaemia and diabetes mellitus on outcomes following heart transplantation', Diabetic Medicine, http://dx.doi.org/10.1111/dme.15441

Lamaro BD; Greenfield JR; Snaith JR, 2024, 'Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes', Journal of Patient Experience, 11, http://dx.doi.org/10.1177/23743735241257811

Hayes AG; Penny MJ; Aivazian K; Greenfield JR, 2024, 'Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly.', JCEM Case Rep, 2, pp. luae071, http://dx.doi.org/10.1210/jcemcr/luae071

Raven LM; Stoita A; Feller RB; Brown C; Greenfield JR, 2023, 'Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists', American Journal of Medicine, 136, pp. e233 - e234, http://dx.doi.org/10.1016/j.amjmed.2023.07.016

Brzozowska MM; Isaacs M; Bliuc D; Baldock PA; Eisman JA; White CP; Greenfield JR; Center JR, 2023, 'Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-33317-6

Milder TY; Milder DA; Greenfield JR; Day RO, 2023, 'Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology', Drug Safety, 46, pp. 1303 - 1305, http://dx.doi.org/10.1007/s40264-023-01358-5

Chavali S; Barua S; Adji A; Robson D; Raven LM; Greenfield JR; Eckford H; Macdonald PS; Hayward CS; Muthiah K, 2023, 'Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices', International Journal of Cardiology, 391, http://dx.doi.org/10.1016/j.ijcard.2023.131259

Hayes AG; Raven LM; Viardot A; Kotlyar E; Greenfield JR, 2023, 'SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes', Diabetes Care, 47, pp. e4 - e5, http://dx.doi.org/10.2337/dc23-1903

Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, 78, pp. 1418 - 1419, http://dx.doi.org/10.1111/anae.16068

Snaith JR; Olsen N; Kowalski G; Bruce C; Holmes-Walker J; Greenfield JR, 2023, 'OR18-03 Peripheral But Not Hepatic Insulin Resistance Associates With Adverse Vascular And Metabolic Health In Type 1 Diabetes: A Possible Target For Adjunctive Therapy', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.895

Raven LM; Muir CA; Kessler Iglesias C; Kotlyar E; Muthiah K; Bart NK; Macdonald PS; Hayward CS; Jabbour A; Greenfield JR, 2023, 'THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.733

Raven LM; Muir CA; Greenfield JR, 2023, 'Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes', Medical Journal of Australia, 219, pp. 293 - 294, http://dx.doi.org/10.5694/mja2.52067

Sheu A; Blank RD; Tran T; Bliuc D; Greenfield JR; White CP; Center JR, 2023, 'Associations of Type 2 Diabetes, Body Composition, and Insulin Resistance with Bone Parameters: The Dubbo Osteoporosis Epidemiology Study', Jbmr Plus, 7, http://dx.doi.org/10.1002/jbm4.10780

Raven LM; Muir CA; Pouliopoulos J; Hayward CS; Macdonald PS; Greenfield JR; Jabbour A, 2023, 'Metabolic Sequelae of Everolimus Treatment After Cardiac Transplant: A Hypothesis-Generating Study', Heart Lung and Circulation, 32, pp. 1076 - 1079, http://dx.doi.org/10.1016/j.hlc.2023.05.014

Back to profile page